Taken together, the data above indicate that the presence of IL-35 in the tumour cell microenvironment might influence the balance between EGFR and PD-L1 under metabolic restriction present in the tumour milieu of NSCLC.27 The gene discussed is EGFR; the disease is neoplasm.